142 related articles for article (PubMed ID: 32940139)
1. Varicella zoster virus myelitis in a patient with rheumatoid arthritis treated by tofacitinib.
Itamiya T; Komai T; Tsuchida Y; Shoda H; Fujio K
Scand J Rheumatol; 2021 Jul; 50(4):319-321. PubMed ID: 32940139
[No Abstract] [Full Text] [Related]
2. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Noell C; Arbeit R; Kanhoush R
Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
[TBL] [Abstract][Full Text] [Related]
3. Elderly-Onset Varicella Pneumonia in a Patient With Rheumatoid Arthritis Treated With Tofacitinib.
Abe N; Kudo T; Jodo S
Arthritis Rheumatol; 2018 Aug; 70(8):1233. PubMed ID: 29648682
[No Abstract] [Full Text] [Related]
4. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
5. [Tofacitinib].
Döker S; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
[TBL] [Abstract][Full Text] [Related]
8. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib: raising awareness of mycoses.
Dyer J; Morwood K; Choong K
Intern Med J; 2019 Jun; 49(6):805-806. PubMed ID: 31185527
[No Abstract] [Full Text] [Related]
11. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
Bannwarth B; Kostine M; Poursac N
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265
[TBL] [Abstract][Full Text] [Related]
17. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
[TBL] [Abstract][Full Text] [Related]
18. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.
Charles-Schoeman C; Fleischmann R; Davignon J; Schwartz H; Turner SM; Beysen C; Milad M; Hellerstein MK; Luo Z; Kaplan IV; Riese R; Zuckerman A; McInnes IB
Arthritis Rheumatol; 2015 Mar; 67(3):616-25. PubMed ID: 25470338
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
